Montreal: December 20, 2024 – AtkinsRéalis, a world-class engineering services and nuclear company with offices around the world, celebrates its completion of work on Novocol Pharma’s state-of-the-art sterile injectable biomanufacturing fill/finish facility in Cambridge, Ontario. AtkinsRéalis’ Industrial team provided services including advisory, design & engineering, procurement, as well as project & construction management to Novocol Pharma as part of the facility’s significant expansion over the past four years. AtkinsRéalis additionally led commissioning, qualification, and validation work, as well as cost estimation, scheduling, risk management, environmental, geotechnical, and LEED building certification services. This project follows many mandates AtkinsRéalis has completed at the site over the past 20 years. The expansion increases Novocol’s capacity and capabilities for its growing CDMO (contract development and manufacturing organization) business.
“Our global, fully integrated, end-to-end capabilities in the Industrial market and deep understanding of the Canadian life sciences sector was key to delivering a successful mandate,” said Stéphanie Vaillancourt, President, Canada, AtkinsRéalis. “As Ontario looks to boost employment in the life sciences sector and attract significant investments, our global experience getting biomanufacturing facilities off the ground positions us as a partner of choice for domestic and international firms looking to expand in Canada.”
Novocol's facility, featuring two lines, will be used to perform formulation, aseptic fill-finish, labelling and packaging of product such as peptides, vaccines, and small molecules. The company has partnered with a global leader in vaccine innovation, who will provide Canadian-made drug substances for Novocol’s drug product operations. This partnership will provided end-to-end capabilities for domestic vaccine supply for both endemic, and pandemic requirements.
AtkinsRéalis’ multi-disciplinary teams from across Canada and the US employed digital engineering techniques including 3D building information modeling (BIM). This allowed for the complex facility to be designed and visualized without the need for a constant on-site presence. The final facility represents an industry leading example in sustainable design for the Canadian life sciences sector.
AtkinsRéalis’ Industrial market has deep experience in the life sciences & pharmaceuticals, advanced/high-tech manufacturing, and general manufacturing spheres across a diverse range of sectors including: pharmaceuticals, biotechnology, food and beverage, chemicals, agrifood & AgriChem, semiconductor/microchip, automotive, EV battery, logistics, data centres, and district cooling. This includes delivering projects such as:
- Expansion of the Jubilant HollisterStier sterile injectable facility in Montreal
- WuXi STA new greenfield cGMP API Manufacturing facility in Singapore
- Medicom N95 Mask Facility in Montreal
- Medicom PPE facility in Northampton
- GSK Vaccine Production Facility Upgrade in Quebec City
- New vaccine manufacturing complex in Incheon for Crucell Korea
About AtkinsRéalis
Created by the integration of long-standing organizations dating back to 1911, AtkinsRéalis is a world-class engineering services and nuclear company dedicated to engineering a better future for our planet and its people. We create sustainable solutions that connect people, data and technology to transform the world's infrastructure and energy systems. We deploy global capabilities locally to our clients and deliver unique end-to-end services across the whole life cycle of an asset including consulting, advisory & environmental services, intelligent networks & cybersecurity, design & engineering, procurement, project & construction management, operations & maintenance, decommissioning and capital. The breadth and depth of our capabilities are delivered to clients in strategic sectors such as Engineering Services, Nuclear and Capital. News and information are available at www.atkinsrealis.com or follow us on LinkedIn.
About Novocol
Novocol is a member of the Septodont Group of companies, a family business headquartered in France. Novocol has been producing injectables for over 45 years at its Cambridge location. The company is a market leader in manufacturing cartridge-based injectable anesthetics and expanded its capabilities over the last ten years to emerge as a leading Fill/Finish CDMO for cartridges, pre-filled syringes and combination products.
Downloads
Trade releases